Based on my reading of this latest newsletter, it sounds like the Brazen Bio that was pitched to investors - the one that was supposed to help launch new biotech companies - is no longer a functional/viable entity. If that's the case, how do you anticipate providing a return to investors?
Based on my reading of this latest newsletter, it sounds like the Brazen Bio that was pitched to investors - the one that was supposed to help launch new biotech companies - is no longer a functional/viable entity. If that's the case, how do you anticipate providing a return to investors?